

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Glow LifeTech Corp. (the "Issuer").

Trading Symbol: GLOW

Number of Outstanding Listed Securities: 81,511,960

Date: May 3, 2024

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Glow LifeTech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. The Company has commenced the build-out and commissioning of licensed processing space to bring a suite of fast-acting, high-absorption, water-soluble cannabis-based ingredients to the Canadian market. Access to the space was obtained through a collaboration agreement with the license holder MEDZ. Glow has a dedicated Processing Space within a fully licensed facility located in Toronto, Ontario, to process, package and distribute cannabis-based concentrates, all in compliance with applicable laws and regulations. The construction, build-out and procurement of all critical processing equipment has commenced.

During the month of February 2023, the Company continued with the development of its high-performance, water-soluble MyCell® cannabis ingredients at its Canadian processing facility. The reactor is a mission critical component of the Company's proprietary MyCell® Technology delivery system which transforms poorly absorbed cannabinoids, like CBD and THC, into water-soluble concentrates that have fast-acting onset, high-absorption and precision dosing.

On March 21, 2023, the Company announced the unveiling of its new brand identity. As the Company advances its commercial plans, Glow is introducing a full top-to-bottom redesign of its logo, colour palette, packaging, marketing materials, and launching a new website. The new brand identity underscores the Company's approach of using advanced technology to unleash the full potential of natural health products. The goal of the rebrand as a whole was to capture the duality of nature and science that is found at all levels of the Company, and to reflect the cutting-edge performance of its products.

On June 28, 2023, the Company announced that it has further accelerated its path to commercialization following its successful pilot-scale production of MyCell® water-soluble cannabis ingredients and the expansion of its cannabis ingredient portfolio with the development of MyCell® and CBG to address the emerging market demand for rare cannabinoids.

On August 16, 2023, the Company announced it has successfully completed its first production and shipment to the Ontario Cannabis Store ("OCS"), marking its entrance into the Canadian adult-use cannabis market. The product is expected to be available in select Ontario retail locations and online at www.ocs.ca in the middle of September 2023.

On April 18, 2024, the Company announced it is currently seeking a new auditor to perform its audit because the Company's current auditor has advised it is unable to continue to perform public company audits. The Company has filed a management cease trade order by the Ontario Securities Commission (the "OSC"), pursuant to the Company's application made under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"). The MCTO is in connection with the delay by the Company in filing its annual audited consolidated financial statements and related management discussion and analysis for the year ended December 31, 2023, by the prescribed deadline of April 29, 2024. The Company does not expect an interruption of the operations of the Company during the CTO. Revocation of the CTO is expected to occur within a few days after the Annual Filings are made.

2. Provide a general overview and discussion of the activities of management.

On August 9, 2023, the Company announced the launch of two cannabis consumer brands in Canada, *MOD* and *.decimal*, with both featuring Glow's portfolio of proprietary liquid and powder cannabis ingredient technologies.

On September 26, 2023, the Company announced it has signed a wholesale distribution and supply agreement with National Cannabis Distribution ("NCD"), for exclusive wholesale distribution and supply in the Province of Saskatchewan. The Company has also successfully shipped its first purchase order of its newly launched *MOD* THC Berry drops to NCD for the Saskatchewan market, building on its recent commercial launch in Ontario in August 2023.

On March 12, 2024, the Company announced the expansion of its product line:

"This product launch represents an important inflection point in our commercial journey, as we more than double our SKUs available for sale in Ontario, with highly anticipated products that we expect to accelerate revenue growth in the near-term," said Rob Carducci, Chief Commercial Officer. "Our unique new products are building off a growing demand for our disruptive brands and are well-positioned for success. MOD™ is already the fastest-growing soluble drops brand in Ontario in 2024 and our .decimal™ capsule innovation are our first THC-containing capsules available which deliver a superior product experience and up to 50% better value than current category leaders."

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

On November 1, 2022, the Company announced the completion of development of its proprietary MyCell® liquid cannabis ingredients, including THC and CBD. The Company now plans for commercialization in the Canadian market, given product readiness. The successful development of MyCell® liquid water-soluble THC and CBD ingredients allows the Company to immediately progress towards scaling-up production and making preparations for selling into the well-established market for THC and CBD products in Canada, as the first step in its global commercial strategy.

On August 2, 2023, the Company announced the launch of two cannabis consumer brands in Canada, *MOD*, and *.decimal*, with both featuring its portfolio of proprietary liquid and powder cannabis ingredient technologies. *MOD* is a brand of naturally flavoured water-soluble drops and *.decimal* is a brand of precision-dosed, fast-acting capsules. Commercial sales activities have commended and based on positive customer traction, the Company expects initial sales as early as September 2023.

On November 7, 2023, the Company announced two additional product lines and successful shipment to the Ontario Cannabis Store ("OCS"), expanding on its recently launched *MOD*™ water-soluble drops and marking the first product launched from its second brand of precision-dosed, fast-acting capsules, *.decimal*™, into the Canadian market.

On March 12, 2024, the Company announced the launch of four new cannabis products in the Province of Ontario, further expanding its innovative *MOD*™ and *.decimal*™ brand portfolio listed by the Ontario Cannabis Store ("OCS"). This is the Company's largest product shipment to-date, more than doubling its active SKUs available for sale in Ontario.

4. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None in the month of April 2024.

- 5. Report on any labour disputes and resolutions of those disputes if applicable.**
None in the month of April 2024.
- 6. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**
None in the month of April 2024.
- 7. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**
On February 16, 2024, the Company announced it has settled an aggregate of \$211,837 of indebtedness owed to an arm's length creditor through the issuance of 4,236,747 units ("Units") of the Company at a price of \$0.05 per Unit (the "Debt Settlement"). Each Unit shall be comprised of one common share in the capital of the Company and one-half a common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant shall be exercisable into one Common Share (each, a "Warrant Share") in the capital of the Company at a price of \$0.07 per Warrant Share until two years from the date of issuance of the Warrants. All Common Shares issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
- 8. Provide details of any securities issued and options or warrants granted.**
On February 16, 2024, in relation to the settlement of the \$211,837 indebtedness, the Company issued 2,118,373 common share purchase warrants. Each Whole Warrant shall be exercisable into one Common Share in the capital of the Company at a price of \$0.07 per Warrant Share until two years from the date of issuance of the Warrants.

On April 26, 2024, the Company announced it has completed a non-brokered private placement financing for gross proceeds of \$605,000 through the issuance of 20,166,667 units in the capital of the Company at a price of \$0.03 per Unit. Each Unit was comprised of one common share in the capital of the Company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one Common Share at a price of \$0.05 per common share for a period of eighteen months from the date of issuance. The Company intends to use the gross proceeds from the Offering for general working capital purposes.
- 9. Provide details of any loans to or by Related Persons.**
None in the month of April 2024.
- 10. Provide details of any changes in directors, officers or committee members.**
On September 7, 2023, the Company announced the appointment of Daniel Proska as a new independent director to the Board of Directors. With over 15 years of experience in senior sales and revenue growth roles across diverse sectors, Mr. Proska has demonstrated a unique capacity for driving business expansion. Notably, his contributions were pivotal in Venus Concepts' growth from \$5 million to over \$100 million in revenue and supporting its growth to a NASDAQ listing.

On April 12, 2024, the Company announced the appointment of Robert Carducci to the position of Chief Executive Officer. Mr. Carducci has previously served the Company's Chief Commercial Officer and Director since inception and has played a pivotal role leading the Company's commercial strategy and execution including sales, marketing, go-to-market and corporate identity. Mr. Carducci is a seasoned CPG and tech-focused business leader

with over a decade of experience at some of the world's most recognizable tier-one CPG companies, including Nestle and Kraft, along with world leading cannabis marketplace and resource tech platform, Leafly. With a unique combination of experience in building large, global CPG businesses and early-stage cannabis and tech startups, Mr. Carducci's broad experience will support Glow's rapidly accelerating commercial growth agenda.

In addition, the Company also announced the appointment of James Van Staveren to the Board of Directors. Mr. Van Staveren has a decade of experience navigating junior public markets, having supported capital raises, M&A, and corporate development initiatives. James currently manages corporate development and investor relations, in addition to his other roles at Scryb Inc. and Cybeats Technologies Corp. James graduated in 2013 with an Economics and Finance degree from Western University. Medhanie Tekeste and Greg Falck have resigned as Directors of Glow. The Company wishes to thank them for their valuable contributions and wish them success in future endeavours.

11. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The market related for Cannabis and Cannabis-related industries are subject to regulatory authorities of each jurisdiction. Glow LifeTech is impacted by changes in regulatory shifts worldwide related to Cannabis.

This document contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects" or, "proposed", "is expected", "intends", "anticipates", "or" "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the Issuer with respect to the matter described in this Monthly Progress Report. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this Monthly Progress Report and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under "Risk Factors" in the Issuer's management's discussion and analysis for the quarter ended September 30, 2023 filed on November 29, 2023 and under "Risk Factors" in the Issuer's annual information form for the year ended December 31, 2022 filed on May 1, 2023, each of which is available under the Company's SEDAR profile at www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this Monthly Progress Report and the Issuer undertakes no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The Issuer cautions investors not to place undue reliance on the forward-looking statements contained in this Monthly Progress Report.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 3, 2024.

Robert Carducci

**Name of Director or Senior
Officer**

"Robert Carducci"
Signature

President & Chief Executive
Officer
Official Capacity

Issuer Details Name of Issuer Glow LifeTech Corp.		For Month End April 30, 2024	Date of Report YY/MM/DD 2024/05/03
Issuer Address 65 International Blvd. Suite 206			
City/Province/Postal Code Toronto, ON M9W 6L9	Issuer Fax No. n.a.	Issuer Telephone No. 855-442-GLOW (4569)	
Contact Name Robert Carducci	Contact Position President & CEO	Contact Telephone No. 855-442-GLOW (4569)	
Contact Email Address rcarducci@glowlifetech.com	Web Site Address https://www.glowlifetech.com/		